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Abstract 
Violent crime and aggressive behaviour are of increasing concern in New Zealand. Much of 
this is displayed by adolescent males who have an association with some form of substance 
use, abuse or dependence. This is especially relevant for stimulant drugs, especially 
methamphetamine (MA), and 1-benzylpiperazine (BZP). Previous research has shown that 
BZP has similar neurochemical and behavioural effects to MA, and there is a large volume of 
research showing an association between chronic MA use and aggression. In contrast to this, 
there has been little research into the consequences of a single administration of MA, which 
is often portrayed by the media as having the same detrimental effects as chronic use. 
The present study was designed to determine whether or not acute MA would induce 
aggressive behaviour in adolescent male hooded rats. In addition, the study also examined 
whether BZP had a similar effect to MA. Sixty male hooded rats aged between 41 to 50 
postnatal days (PND), were utilised and divided into five groups of 12 rats each: saline; 
1mg/kg (low dose) or 2mg/kg (high dose) MA; 10mg/kg (low dose) or 20mg/kg (high dose) 
BZP. The rats were tested using the resident/intruder test of aggression, consisting of eight 
measures of aggressive behaviour. The results suggested that, rats treated with either a low or 
high dose of MA or BZP were significantly less aggressive than saline-treated rats. There 
appeared to be little to distinguish between the two drugs in their effects on the responses 
recorded. It was concluded that an acute administration of either MA or BZP did not increase 
aggression, and thus did not support the view that aggression will result from a single dose of 
MA (or indeed BZP that has not been previously investigated in this context). 
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1.0 Introduction 
 
1.1 General Introduction 
The issue of increasing acts of violence and aggression in New Zealand, as in the rest of 
the world, is a major concern for society as a whole (Fergusson, Boden, & Horwood, 2008; 
Miczek, Fish, de Bold, & de Almeida, 2002; Weinshenker, & Siegal, 2002). The resulting 
costs to victims, the public and even the perpetrators themselves are significant, and of 
detrimental value to society. These detrimental costs include monetary - from court costs, 
imprisonments and police hours - to the more personal issue of injury (both psychological 
and physical) of the victim and those close to them. Of increasing relevance is the more 
serious violent and aggressive crime, which carries more serious and invasive consequences 
to both the victims, and the perpetrators themselves (Sokolov & Cadet, 2006). When 
examining crime in New Zealand, statistics show that crime in general is increasing with 
recorded crime having risen from 396,018 recorded crimes (963.4 per 10, 000 people) in 
2004/2005 to  442,540 recorded crimes in 2008-2009 or 1031.9 per 10, 000. When breaking 
these statistics down to isolate violent crime, a similar pattern emerges with an increase from 
2004/2005 to 2006/2007 when violent offences made up 12.4% of total crime (52,892, or 
125.7 per 10, 000). In 2008/2009 this had risen further to account for 14.2% of total crime 
(62, 874 or 146.6 per 10, 000, Police National Headquarters, 2009). These figures may appear 
small as a percentage, but when aspects such as personal grief and other consequences of 
violence and aggression are taken into account, any number is significant.  
Of note is that most violent and aggressive crime is being committed by young males 
who have an association with some form of substance use, abuse or dependence (Armstrong 
& Costello, 2002; Fields & McNamara, 2003; Pellegrini, 2002). This association has long 
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been acknowledged as causing these more violent or aggressive responses, and is supported 
by an extensive volume of literature on the relationship between stimulant substances and 
aggressive behaviour. This is especially so for stimulant substances, which increase 
behavioural activity, and include cocaine and the amphetamines. Due to its more inaccessible 
nature, New Zealand is not influenced by the use of cocaine in comparison to other countries, 
but stimulants such as methamphetamine (from here on referred to as MA) are more readily 
available, produced and used here by offending young people. Because of this, research into 
aggressive behaviour resulting from the use of MA is of more relevance and importance to 
New Zealand than research into other stimulants such as cocaine. But what needs to be 
acknowledged is that, although there is a general acceptance of an association between drug 
use and aggression and violence, the relationship is not a simple causal one as many other 
factors can influence this association.  
There is conflicting evidence regarding the issue of whether or not chronic or acute 
doses of MA are related to aggression.  In particular, there has been very little research into 
the consequences of a single administration. Of all the studies examined by the present 
author, only one concluded that an acute dose administered to rats resulted in aggressive 
behaviour (Crowley, 1972). This was in comparison to studies of chronic use in both animals 
and humans which concluded there was a relationship between MA use and aggression.  
Especially important is the fact that MA use is portrayed by the media through news bulletins 
and internet websites (Tyner & Fremouw, 2008) as being an absolute for causing aggression, 
often suggesting that even a single experience with this drug will lead to dependence and 
behaviour change. 
A commonly used drug that is similar to the effects of MA, both neurochemically 
(Baumann et al., 2005) and behaviourally (Herbert & Hughes, 2009), is 1-benzylpiperazine 
(BZP).  This drug is the principle ingredient of ‘party pills’ (STANZ, 2005) and was only 
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recently reclassified in New Zealand as a restricted substance in the same general category as 
the amphetamines.  Given the similarities between MA and BZP, it is not inconceivable that 
BZP might also increase aggressive behaviour, but to date there is little research showing the 
detrimental effects of its use. 
Compounding the issue of how these two drugs may affect aggression is the problem of 
the media and how they portray these substances and the detrimental effects of using them. 
According to popular belief, which is highly influenced by the media, someone who takes 
MA once is then addicted, and hence prone to all the detrimental effects associated with 
chronic use or addiction (Tyner & Fremouw, 2008). Throughout New Zealand schools there 
are antidrug use campaigns in which it is stated that a single experience of MA can turn one 
into an aggressive person, even though there is very little research to support this stance. BZP 
is of less interest to the media, but this may be a result of the lack of knowledge surrounding 
the drug and its detrimental effects. 
An understanding of how these two drugs may influence adolescent aggressive 
behaviour might help to reduce the associated crime and detrimental consequences 
experienced by victims and the perpetrators themselves. Furthermore, intervention during 
adolescence might reduce the chances of adult use and abuse and the incidence of associated 
aggressive behaviour. An important consequence of such research could be the better 
understanding of this complex relationship. This could then result in the reduction of the 
significant costs associated with adolescent crime committed while under the influence of, or 
dependence on a substance. 
 
1.2 Aggression  
Consistent with the need for sound scientific research on aggression, there has been a 
noticeable increase in research in this area. This has been directed towards the better 
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understanding of the origin, classification, underlying mechanisms, and treatment of the 
aggressive behaviour that makes up the state of aggression (Hinshaw & Lee, 2003). It is 
generally accepted that the concept of aggression is multidimensional and difficult to define 
and measure, with no universal language that enables consistent communication of findings 
(McEllistrem, 2004).  However, it is important to overcome these deficiencies because 
aggression is a huge problem for public health and criminal justice (Cohen, Hsueh, Russell, 
& Ray, 2006; Hoaken & Stewart, 2003; Miczek et al., 2002; Parrott & Giancola, 2007; 
Ramirez, 2003; Weinshenker & Siegal, 2002). Parrott and Giancola (2007) add that because 
aggression can be expressed behaviourally in a myriad of ways, current research suffers from 
limitations in measurement, known as the criterion problem. This is the issue of variation 
between individuals in the way they behave and the difficulty researchers have in 
incorporating all these variations into one construct such as aggression (Austin & Villanova, 
1992). 
Another problem in the research on aggression and violence is that the two terms are 
often used interchangeably in studies that have been published. It is generally agreed that 
aggression is an empirical term; a verifiable behaviour based on biology, whilst violence is a 
social construction that is very difficult to measure by experimentation, and is influenced by 
cultural, environmental and social aspects (Weinshenker & Siegal, 2002). Violence would 
involve the concept of aggression, and aggressive responses that result from this state. 
Another view is that aggression and violence are on a continuum with violence as an 
extreme form of aggression (Hoaken & Stewart, 2003; Ramirez, 2003). Ramirez also states 
that even though biology is an important factor, other aspects must also be acknowledged. 
Furthermore, as with other species, humans may have inherited a biological basis for 
aggression as a means of protection in their striving for survival. The difference with humans 
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is that they have a unique capability for intelligence and learning which can be applied to 
behaviour (Ramirez, 2003).  
When attempting to define aggression, there is agreement that it usually pertains to the 
actions of a person towards another with the intention of causing physical or mental harm 
(McCormick & Smith, 1995; Weinshenker & Siegal, 2002). Most researchers agree that 
aggression involves the goal-directed, intentional behaviour of harming another person who 
perceives this behaviour as aversive and is motivated to avoid it (Hoaken & Stewart, 2003; 
Miczek et al., 2002). The idea of intention is important because it highlights the role of 
cognitive components, and their possible dysfunction through the effects of drugs (Hoaken & 
Stewart, 2003). It is also accepted that the neurochemicals involved in aggression include 
dopamine (DA) and serotonin (5-HT).  Drugs that target D2 receptors facilitate aggressive 
behaviour in both animals and humans (Miczek et al., 2002; McEllistrem, 2004), whereas 
drugs that act on 5-HT exert an inhibitory action on the responses (McEllistrem, 2004). It is 
acknowledged that the results of research on DA are mixed, but importantly there appears to 
be an interaction between the effects certain substances have on these two neurotransmitters 
and their relationship with aggression. 
Aggression has been divided into various subtypes. For example, Parrott and Giancola 
(2007) regard aggression as a behavioural process that needs to be distinguished from related 
constructs such as hostility and anger. It is possible to feel angry or hostile, but not engage in 
aggressive behaviour, yet it is very difficult to act aggressively without feeling angry or 
hostile. To act in this latter way involves the concept of psychopathy, which is a rarer and 
serious personality type (Frick, Cornell, Barry, Bodin, & Dane, 2003; Hare, & Mcpherson, 
1984). Separating out these different terms will help to better understand the concept of 
aggression and how it develops. Parrott and Giancola (2007) state that there can be hostile 
aggression (goal directed) and instrumental aggression (infliction of pain being the intent of 
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the behaviour) as well as proactive (bullying, threatening) or reactive (retaliatory), and direct 
or indirect/relational. Aggression can also be verbal or physical. Physical aggression is 
especially important, because as development progresses to adolescence, this type of 
aggression can become violent and assaultive, which often has more detrimental outcomes 
for the victims (Hinshaw & Lee, 2003; Weinshenker & Siegal, 2002). Other subtypes of 
aggression are inter-male, irritable (resulting from influences such as intense heat, hunger 
and thirst), sex-related, predatory and territorial. Many of these subtypes are evident in the 
resident/intruder aggression test where an intruder rat is placed into the home cage of a 
resident rat (Weinshenker & Siegal, 2002). Other researchers use competitive aggression, 
which is similar to inter-male because of the desire to be the best, dominant male. This 
competitive/inter-male aggression occurs between two males, and is very common in the 
animal kingdom, and is relevant to humans because of the high frequency of violent acts 
involving at least two males. Whatever the label or subtype an aggressive response is 
assigned to, all types of aggressive behaviour commonly occur when two males are placed in 
close proximity to each other, because of this possible inherent tendency to be the dominant 
male (Weinshenker & Siegal, 2002).  
All of these definitions can be incorporated into the concepts of affective defence and 
predatory attack. There is considerable agreement that most definitions can fit under these 
two categories, and that much animal and human aggression contains affective or predatory 
characteristics. In addition, using these two categories will help to link human and animal 
research together, while also leading to new investigations (Weinshenker & Siegal, 2002). 
Subtypes such as fear-induced, inter-male, irritable, sex-related and territorial aggression are 
incorporated under affective defence because they all share the common feature of being an 
aggressive response based upon the presence of elements of fear and/or threat that are either 
real or perceived (Weinshenker & Siegal, 2002). McEllistrem (2004) supports the predatory 
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and affective aggression classification, and adds that the terms are used throughout the social, 
forensic, clinical and biopsychological literature, and that both neurochemical and anatomical 
studies support this classification. This classification of aggression incorporates and 
acknowledges both biology, through unique physiological substrates, and phenotypic 
expressions of aggression, which is the behavioural expression that results (McEllistrem, 
2004). Parrott and Giancola’s (2007) subtypes of aggression also fit into these two subtypes; 
hostile aggression involves affective and impulsive aggression, and is an unplanned act 
intended to harm another, whereas instrumental aggression is a premeditated act where the 
primary goal is to obtain some other incentive, and fits with predatory attack. 
Predatory attack appears to be less common and, in humans, may possibly be related to 
rarer forms of psychopathy, and hence more difficult to measure, whilst affective defence is 
common to both humans and animals so is easier to measure and understand. 
 
1.2.1 Affective Defence 
The concept of affective defence has been used in research and published studies over 
the past 40 years, and is defined in both human and animal literature as an aggressive 
response based on the presence of elements of either fear and/or threat, which may be real or 
perceived, and has the goal to reduce or eliminate threat and thus reduce tension 
(Weinshenker & Siegal, 2002). In animal research this type of aggression occurs in the 
presence of another animal that is perceived to be a threat and has basic elements like 
piloerection, paw strike, shrinking or lowering of body. Research related to human behaviour, 
deals with affective defence for which the goal of reducing or eliminating threat and reducing 
tension is related to episodic control characterised by an explosive personality in the absence 
of impulse control (Weinshenker & Siegal, 2002).  Researchers believe that this behaviour in 
humans is often associated with psychiatric problems such as paranoia and altered perceptual 
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states, and is believed to be a response to stimuli that evoke anger and fear (Weinshenker & 
Siegal, 2002). Also in support of the affective defence subtype is the fact that many 
psychometric tests (such as the Buss-Durkee Hostility Scale and the Overt Aggression Scale) 
are designed to measure aggression of this type because it is easier to measure than predatory 
aggression (Weinshenker & Siegal, 2002).  
To better understand the link between substance abuse and aggression in adolescents, it 
is necessary for there to be agreement on the definitions and possible subtypes of aggression. 
This would provide more consistent and reliable results in the research. Therefore, this 
present study will examine the affective defence subtype of aggression. 
 
1.3 Adolescence and Violence/Aggression 
There is a general consensus that adolescence is a transitional phase in development 
during which major physical and psychological changes occur that result in a very different 
behavioural repertoire from what was previously characteristic (Ramirez, 2003; Smith, 2003; 
Spear, 2007a). From a biological perspective, adolescence is a time of considerable neural 
development in the brain. Areas such as the mesocorticolimbic region and the pre-frontal 
cortex (PFC) are especially important because of the numerous changes in DA production 
and utilisation that occur there. This is in addition to these areas of the brain being part of the 
circuitry critical for modulating risk behaviour and social behaviour, and for attaching 
motivational relevance to natural rewards and drugs (Spear, 2007b). This period of change 
and experimentation involves the use of illicit substnces, which is a common aspect of 
adolescence (Baskin-Sommers, & Sommers, 2006; Chambers, Taylor & Potenza, 2003; 
Smith, 2003; Spear, 2007b). Smith (2003) states that adolescence is a time when young 
people are particularly vulnerable to substance abuse and that the effects these drugs have on 
the developing brain are different from those for adults. The different effects for adolescents 
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in comparison to adults is especially so for MA thereby making them a clinically challenging 
population (Clingempeel, Britt, & Henggeler, 2008).  
The use of substances during adolescence has been shown to be related to a number of 
psychiatric problems including low self esteem, anti-social behaviour, and later, more serious 
drug use and abuse, crime and aggression (Armstrong & Costello, 2002; Stansfield & 
Kirstein, 2005). Lansford, Erath, Yu, Pettit, Dodge and Bates, (2008) support and provide 
evidence for these short and long term problems associated with substance use in 
adolescence, stating that previous research links substance use with externalising disorders 
which include aggressive behaviour and violence. From the results of their study involving 
585 young people in the Child Development Project, it was concluded that substance use 
disorders were more common with externalising disorders like aggressiveness than 
internalising disorders like depression at age 18. In a review by Armstrong and Costello 
(2002), it was found that 60% of young people with a substance use, abuse or dependence 
problem also had a co-morbid psychiatric diagnosis. They stated that child psychopathology 
was strongly associated with early onset substance use and abuse in late adolescence. A study 
in New Zealand supported this finding of child psychopathology being associated with 
substance use problems in adolescence. This study reported that illicit drug use from the age 
of 16 to 25 was associated with a wide range of early life circumstances such as parental use 
of illicit substances, gender and conduct problems. Being exposed to parental substance use, 
being a male and having co-morbid conduct problems greatly increased the chances of 
substance use problems in adolescence (Fergusson et al., 2008). In addition, the highest rates 
of referral to mental health services for this age group involve aggressive acting-out patterns 
of behaviour (Hinshaw & Lee, 2003).  
The increasing interest in the alarming rates of violent and aggressive acts, including 
murder, committed by adolescents has resulted from notorious instances of youth violence in 
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recent years (Fields & McNamara, 2003; Pellegrini, 2002). The mean age of perpetrators is 
reported to be declining, and many different reasons have been proposed for why youth 
violence is increasing. These reasons include social learning, where a young person may 
learn aggressive behaviour by observing a parent behaving the same way; and, attribution, 
where they may make unfounded assumptions about another’s intentions so that they are 
malevolent or cruel. This aspect may relate to the adolescent’s changing cognitions during 
this period as well as the cognitive changes induced by substance use leading them to 
misinterpret the intentions of others. Other reasons include resilience, developmental and an 
eclectic view. This eclectic view for why youth violence is increasing involves a combination 
of all the other reasons, and incorporates substance use. This inclusion of all aspects 
acknowledges the great complexity of understanding why behaviour occurs. 
New Zealand statistics on youth offending describe a noticeable increase in the number 
of youth apprehensions for violent offences over the period 1995 to 2006. In 1995 there were 
2,690 violent offences, which increased to 3,743 violent offences in 2006. This equated to an 
overall increase of 39%. For the 2006 year, 24% of all prosecuted cases involved a violent 
offence (1,486 violent offences out of 6,202 offences), and across all age groups 
approximately one in seven apprehensions made by Police was of a 14 to 16 year old. This 
equated to 30,451 apprehensions of this age group out of a total of 203,484 apprehensions 
across all groups. In just one year from 2005 to 2006 there was a 9% increase in violence 
offences, which was reported to be due to a large increase in recorded grievous or serious 
assaults (1,324 apprehensions to 1,512). Also of note is that between 77% and 80% of these 
apprehensions were by male youth (Chong, 2007). This overwhelming statistical evidence for 
the problem of adolescent crime and violence, in combination with the acknowledged 
changes in brain functioning supports the need to understand why this problem exists for this 
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age group. Therefore, the present study will focus on this age group in the hope of adding to 
our understanding of how drugs affect the group.  
 
1.4 Aggression and Substance Abuse 
There is abundant research supporting the link between aggression and substance 
abuse, and highlighting its subsequent cost to those involved. There is consensus that the 
links between psychoactive substances and violence or aggression involve many different 
factors, including social, economic, psychosocial, psychological and biological influences. 
These are the processes that underlie all human behaviour, but the relationship is complex, 
and it is often more suggestive, than conclusive, emphasising the complexity of the 
relationship (Boles & Miotto, 2003; Friedman, 1998; Grimes, Ricci, Rasakhan, & Melloni Jr, 
2006; Hoaken & Stewart, 2003; Homer, Solomon, Moeller, Mascia,  DeRaleau, & Halkitis, 
2008; McKetin  McLaren, Riddell, & Robins, 2006; Sokolov & Cadet, 2006; Sokolov, 
Schindler, & Cadet, 2004). In addition, to date there has been very little research into this 
relationship in adolescents (Grimes et al., 2006). 
Hoaken and Stewart (2003) divided the direct ways drugs can affect the user into three 
categories. Firstly: direct pharmacological effects (intoxication), secondly: neurotoxic, which 
involves damage to the brain and neurotransmitters from prolonged use, and thirdly: 
withdrawal. These researchers have also subdivided intoxication into four physiological 
effects that are likely to increase the chances of aggression. The first of these is: alteration of 
the psychomotor system. This results in the enhancement of excitation and reward, such as an 
increase in approach, sensation seeking and/or attack responses which would not otherwise 
be performed. Psychomotor stimulant properties therefore appear to potentiate violence by 
means of amplifying behaviour which could be characterised as risky, such as approach and 
engagement. The second effect is alteration of the anxiety and/or threat system, and the third 
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is alteration of the pain system. Affective defence is an unconditioned response, so drugs that 
heighten pain sensitivity would therefore increase the likelihood of defensive aggression. 
Lastly, the fourth effect is alteration of certain higher order cognitive capacities. The 
alteration in the ability to formulate behavioural strategies is an example of the fourth effect 
(Hoaken & Stewart, 2003). This alteration of higher order cognitive capacities also includes 
changes in mood and feelings of anxiety, which could help to result in aggression through a 
person’s heightened state of arousal, and thus involves the flight and flight mode of response. 
Fight mode if activated would logically include aggression and possibly violence, and is 
supported by a number of results (Cancela, Basso, Martijena, Capriles, & Molina, 2001; Craske 
& Barlow, 2008; He, Xu, Yang & Li, 2005; London, Simon, Berman, Mandelkern, Lichtman, 
Braman, et al., 2004). 
Because substance abuse occurs in many different contexts, the relationship between 
aggression and substance use is also moderated by many different factors in both the 
individual and the environment. Each of these different factors can influence the potential for 
violence or aggression to manifest itself in a person’s behaviour. This leads to the problem of 
inferring causality to a single aspect, which is a weakness in the research on this relationship 
(Seddon, 2000). In addition, violence or aggression can occur at different stages of drug use, 
from acute intoxication, to dependence, to drug seeking behaviour. Such behaviour is 
associated with alleviating the unpleasant symptoms of withdrawal and, in the case of 
stimulant use, episodes of drug-induced psychosis and paranoia (Boles & Miotto, 2003). 
Seddon (2000) reported that most researchers use uni-directional mechanistic ‘cause-and-
effect’ models. Three of the most commonly used models to understand the relationship 
between substance abuse and aggression and/or crime are: 1) drug use leads to crime 2) crime 
leads to drug use 3) both are related to other factors. Acknowledging that all three models, or 
aspects of each, may play a role in this relationship, acknowledges the problem of causality. 
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It is difficult to infer that there is a single mono-directional cause for drug use leading to 
crime. This mono-directional concept of the relationship has support throughout the 
published research (Wilkins, Griffiths, & Sweetsur, 2009).  Wilkens et al. (2009) state that if 
there was indeed a bi-directional cause of drug use leading to crime, there would be no crime 
if drugs were freely available. Clearly this is not the case, meaning that researchers must 
acknowledge that there are other factors playing a role in the substance 
abuse/aggression/crime relationship, which is therefore better classed as an interactive 
relationship. This view fits with Goldstein (1985, cited in Boles & Miotto, 2003) who states 
that there are three ways that substance abuse is related to aggression or violent acts, for 
which there is support (Tyner & Fremouw, 2008). The first is Psychopharmacological 
Violence – where the aggressive behaviour is performed whilst under the intoxication of 
substances. This violent behaviour can occur through changes in brain functioning resulting 
from both short and long term use of drugs that produce irritability, excitability, paranoia or 
violent behaviour. This is the biological aspect of the relationship between drug use and 
aggression. The biological links between psychoactive substance abuse and violence or 
aggression differ by the type of drug, amount, and pattern of use (Boles & Miotto, 2003; 
Friedman, 1998), and incorporates Hoaken and Stewart’s (2003) aforementioned ways that 
drugs can effect a user, as well as including the four  physiological effects of intoxication. 
This type of violence also includes changes or impairments in cognitive functioning 
resulting in the misinterpretation of the intentions of others. This can be impacted upon by 
intensified emotional states which relate to high and low mood, and increase in DA and 
reduction of 5-HT, or disruptions of hormonal or physiological functions that motivate or 
restrain violence (Friedman, 1998). Friedman (1998) states that the psychopharmacologic 
dimension involves effects on behaviour like excited, irrational violent impulses or a direct 
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biological effect on the structure of the brain, or a temporary physiological effect on the brain 
function that causes cognitive dysfunction i.e., misinterpret others’ actions. 
Although it is undeniable that biological factors alone do not cause violence, it is also 
very clear that some do play a major role in the aetiology of aggression. As stated, the 
neurotransmitters frequently cited as the key biological correlates of aggression are 5-HT, 
and DA, and it is clearly shown that stimulant substances affect these neurotransmitters 
(Anderson, 2005; Boles & Miotto, 2003; Bondar, & Kudryavtseva, 2005; Couppis, & 
Kennedy, 2008; Higgins & Katz, 1998; Julien, 2001). Low 5-HT is the most cited factor in 
the research, but this is probably an over simplification, as the issue is believed to be more 
complex than just a depletion of 5-HT, and is possibly more predictive of impulsive 
disturbances, depression or anxiety (Boles & Miotto, 2003). DA is involved not only with the 
pleasurable effects of taking a drug, but also behavioural regulation so this neurotransmitter 
might play a part in modulating human aggressive behaviour (Boles & Miotto, 2003). It is 
important to note that drugs affect the functioning of these transmitters, thereby possibly 
causing a confused person to experience many different emotions and cognitions. 
The second way substance abuse is related to aggression or violent acts is Systemic 
Violence. Systemic violence refers to the aggressive responses displayed during the 
interaction within the system of drug distribution and use. An example of this type of 
violence is a murder or assault resulting from conflict over drug turf. The resulting threat of 
violence to the public creates environments of fear and intimidation for many communities 
(Hinshaw & Lee, 2003). In New Zealand people recently apprehended and detained in watch 
houses that participated in a programme for measuring drug and alcohol use said that selling 
amphetamines (including methamphetamine) involved the most risk and was perceived to be 
the most violent drug market (Hales & Manser, 2007; Wilkens, Girling, Sweetsur & Butler, 
2005).  
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The third way substance abuse is related to aggression or violent acts is Economic 
Compulsive Violence. This way is related to the acquisition of drugs and the money needed to 
sustain a habit, which in some cases can reach very expensive proportions rapidly. There is 
significant overlap between all three types, and in support of systemic and economic 
compulsive violence is the fact that it is inevitable that criminal activity will occur within the 
black market world of drug trading (Tyner & Fremouw, 2008).   
In New Zealand, there is evidence of all three types of aggression, and the relationship 
with drug use is clear.  The increasing trend over the last decade or so, especially in regards 
to the use of amphetamines, which includes MA, is also evidenced. Crime relating to 
substance abuse was the fourth highest major offence in 2003. For the year ending 30th June 
2007, this had risen to be the second largest major offence, behind dishonesty (New Zealand 
Department of Corrections, 2003). Drugs and anti-social crime accounted for 13.3% of 
recorded crime in 2007 (Police National Headquarters, 2007), and has risen to account for 
15.2% in 2009 (Police National Headquarters, 2009). In relation to offenders themselves, a 
study of psychiatric morbidity in New Zealand prisons showed that 46.2% of females met 
criteria for abuse or dependence of a substance (other than alcohol or cannabis), 38.4 % 
remand males met criteria, and 36.9% sentenced males met criteria (Simpson, Brinded, 
Laidlaw, Fairley & Malcolm, 1999). This emphasises the point that although aggression and 
violence is associated with substance use, many other factors play a role in determining who 
will actually be affected by this relationship. 
Although the relationship between substance abuse and aggression is complex, a better 
understanding of this complexity will develop from research that investigates all the different 
aspects of the link. By examining whether a single dose of a drug may cause aggression, this 
study will endeavour to deepen the understanding of this complex relationship. 
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1.5 Stimulants 
Because of the aforementioned relevance of MA and BZP to New Zealand, it is the 
stimulant class of drug that is of importance in this study, especially the amphetamines which 
includes MA. Stimulants are the class of drug with the most idiosyncratic literature regarding 
their relationship to violence, with mass media playing an important role in making people 
believe that they undeniably generate aggression. Yet the experimental literature is 
inconsistent, and there is agreement to acknowledge other reasons for the link between 
stimulants and aggression (Hoaken & Stewart, 2003). Hoaken and Stewart (2003) state that 
one pertinent aspect is the fact that people who tend to use stimulants may be more likely to 
be aggressive and also have antisocial personalities, which could imply that they enjoy the 
stimulation that these substances provide. Anderson (2005) adds that the effects of different 
stimulants at different developmental periods can have unique short and long term effects. 
This supports the importance of understanding how drugs affect adolescents. 
A substance belonging to the stimulant category, also known as a ‘psycho-stimulant’, 
tends to increase behavioural activity. Examples of this increased behavioural activity are 
elevation of mood, increases in motor activity, alertness, and the brain’s metabolic and 
neuronal activity. Stimulants have been shown to directly stimulate the nucleus accumbens 
(NA), which is associated with the pleasure pathway, behavioural reinforcement, and the 
compulsive abuse and dependency of these substances (Anderson, 2005; Couppis, & 
Kennedy, 2008; Julien, 2001; Spear, 2007b). 
Amphetamines are a structurally defined group of drugs belonging to this stimulant 
group of substances that affect both the central nervous system (CNS) and the autonomic 
nervous system (ANS). The CNS is affected by the aforementioned release of DA from pre-
synaptic storage sites in nerve terminals. Hence, the drug is a potent DA agonist, and also 
inhibits reuptake of DA (Anderson, 2005; Baumann, Clark, Budzynski, Partilla, Blough, & 
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Rothman, 2005; Boles & Miotto, 2003; Carlson, 2004; Julien, 2001). Studies also show that 
stimulation of the DA receptors in the mesolimbic system (which includes the NA) causes 
behavioural stimulation and increased psychomotor activity. The high dose stereotypical 
behaviour appears to involve DA neurons in the caudate nucleus and putamen of the basal 
ganglia (Julien, 2001: Carlson, 2004). There is agreement that the actions leading to increases 
in aggressive behaviour are complex, and the harmful effects seen in high-dose users include 
psychosis and other abnormal mental conditions (Brems & Johnson, 2001; Wilkens, Sweetsur 
& Casswell, 2006). These users show deterioration in social, personal and occupational 
characteristics, and often experience paranoid ideation. This psychosis is especially 
evidenced with MA.  
Amphetamines are also prone to compulsive abuse. Cocaine and amphetamines are 
believed to initially cause excess transmitter followed by a state of depletion which is 
presumed to be associated with changes in mood that may predispose aggression. In addition, 
withdrawal from these drugs produces a set of characteristic physical and psychiatric effects, 
and it is the pursuit to alleviate these effects with drugs that can also develop into aggressive 
behaviour (Boles & Miotto, 2003). 
Physical dependence on amphetamines is readily induced in both humans and animals, 
and follows a classical positive conditioning model. That is, the positive reward received 
through the pleasurable high, leads to further use and abuse. Tolerance for amphetamines 
develops rapidly and often results in a need for higher doses. This can result in a vicious 
cycle of use and withdrawal, involving a need to acquire the drug and sustain a habit. The 
tolerance combined with the memory of the high leads to further intake, social withdrawal 
and a focus on procuring drug (Julien, 2001). This demonstrates a combination of all three of 
Goldstein’s ways that propose how substance abuse can be related to aggression.  
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The findings of the research on chronic or acute use of these stimulants producing 
aggression are mixed, with most of the research stating that it is chronic use of these 
stimulants that produces the more aversive effects including aggression (Boles & Miotto, 
2003), whilst stating that substance induced aggression during intoxication/use can occur in 
dependent or nondependent users. Boles and Miotto (2003) report that the significant 
consequence of chronic use is development of behavioural pathology including paranoid 
psychosis, impaired reality testing and hallucinations, and that this psychosis has been 
described as transient, prolonged or persistent. They also report that amphetamine use 
produces irritability, physical aggression, hyperawareness, hyper vigilance and psychomotor 
agitation, whereas chronic intoxication can produce a psychotic, paranoid state, including 
frightening delusions. Increased dosage was found to be associated with delirium involving 
confusion, fear and anxiety, delusions, paranoid thinking and compulsive behaviour. Boles 
and Miotto (2003) conclude that amongst the most important effects of amphetamines are 
mood altering properties which can occur with both acute and chronic administration, and 
that psychosis induced more by amphetamines than cocaine or other stimulants maybe 
because of longer duration of action (longer half-life). Chronic use of amphetamines is 
associated with violence more than any other psychoactive substance. 
Forensic and clinical literature clearly demonstrates an association between cocaine 
abuse and aggression, or acts of violence that arise from the direct pharmacological effects of 
cocaine for both causal and chronic users (Boles & Miotto, 2003; Davis, 1996; Friedman, 
1998; Higgins & Katz, 1998; Long, Wilson, Sufka, & Davis, 1996). On closer examination 
the results are mixed with inconsistent results, and different results for chronic and acute use. 
There is agreement that it is not a simple direct pharmacological effect, but a possibly 
interplay of all different aspects (Hoaken & Stewart, 2003) possibly including all of the 
aforementioned ways substance can affect violent or aggressive behaviour. Another problem 
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with the research examining the relationship between illicit drugs and aggression is that all 
the different substances are often combined. To gain a better understanding of how each 
substance may be related to aggression, it would be better to examine each substance 
separately (Boles & Miotto, 2003).  
 
1.6 Methamphetamine (MA) 
1.6.1 General 
Methamphetamine use has increased significantly over the last decade, fast becoming a 
world wide problem that is now recognised by the public, the criminal system and researchers 
(Butler, Wheeler, & Sheridan, 2009; Darke, Kaye, McKetin & Duflou, 2008; Homer et al., 
2008; Maxwell, 2005; McKetin et al., 2006; Richards, Bretz, Johnson, & Turnipseed, 
Brofeldt, & Derlet, 1999; Tyner & Fremouw, 2008; Wu, Pilowsky, Schlenger, & Galvin, 
2007). In the adolescent age group, MA is now the second most used drug after marijuana in 
over 36 countries, and this age group is now identified as the key group at risk of MA use 
(New Zealand Police, 2009; Wu et al., 2007). The extent of the problem, and the severe 
consequences of the use and abuse of MA, is so great that it is now referred to as the Meth 
Menace (Tyner & Fremouw, 2008).  
Methamphetamine, as with amphetamine, is highly addictive and often abused. 
Exposure early in life has lasting effects on cognitive processes (McFadden, & Matuszewich, 
2007; Rothman & Baumann, 2003; Volkow, Chang, Wang, Fowler, Leonido-Yee, 
Franceschi, et al., 2001). This is compounded by the ease with which it can be synthesised 
from general household products like drain cleaner, and ephedrine and pseudoephedrine, 
which can be found in common cold and ‘flu remedies (McFadden, & Matuszewich, 2007; 
New Zealand Police 2009; Tyner & Fremouw, 2008; Volkow et al., 2001; Wilkins et al., 
2009). 
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1.6.2 Biology/ Neurotransmitters 
Methamphetamine has a chemical structure similar to amphetamine, but with a methyl 
group in the terminal amino group (Grimes et al., 2006). MA affects the CNS more potently 
because it is a cationic lipophilic molecule affecting both the sympathetic nervous system 
(SNS) and CNS, and hence is more potent than amphetamine because of its lipophilic nature 
which allows greater penetration of the CNS (Homer et al., 2008; Julien, 2001; McKetin et 
al., 2006; Tyner & Fremouw, 2008).  
Compared with cocaine, which is acknowledged as being associated with aggression 
and violence, Ice (which is a 90-100% pure form of methamphetamine) is very similar to 
crack cocaine. The effects of Ice closely resemble and are frequently indistinguishable from 
cocaine. The main difference is that Ice has an extremely long half-life of up to about 12 
hours. This results in an intense, persistent drug action, as well as building tolerance much 
quicker, meaning the user requires more and more of the drug to get the same effect (Cartier,  
Farabee, & Prendergast, 2006; Julien, 2001; Wu et al., 2007). This can in turn lead to 
aggression and violence through all three aforementioned ways through more intense 
biological effects combined with a greater need to acquire more of the drug at a greater cost 
financially. It is also agreed that these repeated high doses are associated with violent 
behaviour and paranoid psychosis (Julien, 2001; Maxwell, 2005). Julien (2001) goes on to 
say that these high doses cause long-lasting decreases in 5-HT and DA in the brain, because 
the toxic effect targets the neurons that manufacture both of these neurotransmitters (Boles & 
Miotto, 2003; Homer et al., 2008; McKetin et al., 2006; Sekine, Ouchi, Takei, Yoshikawa, 
Nakamura, Futatsubashi,  et al., 2006). Many researchers agree that studies have indicated 
that chronic use decreases DA in the NA (Carlson, 2004; Couppis & Kennedy, 2008; Payer, 
Lieberman, Monterosso, Xu, Fong, & London, 2008; Sokolov & Cadet, 2006). This decrease 
in DA in the NA can result in unpleasant feelings if the drug is stopped, thus leading to 
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dependence though negative reinforcement as the user ties to alleviate the unpleasant feelings 
by taking more of the drug. Julien (2001) also says that Ice produces patterns of delusional 
and psychotic behaviour, but unlike cocaine, this psychosis can persist for several weeks. 
McKetin et al. (2006) state that, for there to be a causal relationship between MA and 
aggression, there needs to be a plausible biological pathway through which MA use causes 
violence. The recognised dysfunctioning of neurotransmitters would support this pathway. 
But as stated previously, it is clear that this is just one aspect of how the two concepts are 
related, and all the others need to be considered in any conclusion.  
 
1.6.3 Aggression 
There is an abundant amount of research reporting a relationship between MA and 
aggression, especially affective defence (Weinshenker & Siegal, 2002). The key role of 
biology, through changes in neurotransmitters is acknowledged, yet most researchers agree 
that the relationship is complex and multi dimensional. Many other factors such as co-morbid 
psychiatric problems and systemic violence like drug trafficking play a role, hence inferring 
causality is very difficult (Austin, 2004; Baskin-Sommers, &  Sommers, 2006; Boles & 
Miotto 2003; Brecht, O’Brien, von Mayrhauser,  & Anglin, 2004 ; Cartier, et al., 2006; 
Grimes, et al., 2006; Hall, Hando, Darke, & Ross, 1996; Homer, et al., 2008; Maxwell 2005; 
McKetin et al., 2006;  Miura, Fuliki, Shibata,  & Ishikawa, 2006; Payer et al., 2008; Sekine et 
al., 2006; Sheridan, Bennett, Coggan, Wheeler, & McMillan, 2006; Sokolov, et al., 2004; 
Sokolov & Cadet, 2006; Tyner & Fremouw, 2008). Boles and Miotto (2003) emphasise the 
fact that MA use contributes to aggression through both the pharmacological effects, such as 
agitation, paranoia and psychosis, and the systemic violence factors such as drug trafficking. 
Route of administration has also been shown to make a difference with injection being related 
to significantly more aggressive behaviour (Hall et al., 1996). Disorganised cognitions, 
 23
involving paranoia and psychosis are usually related to persecutory delusions and perceived 
threat, and are the commonly associated psychiatric problems associated with chronic use of 
MA and resulting aggression (Baskin-Sommers, &  Sommers, 2006; Maxwell, 2005; 
McKetin et al., 2006; Wilkins et al., 2009). This results from the misinterpretation of others’ 
intentions, and perceived threat which can instigate a violent reaction (Cartier et al., 2006). 
Cartier et al’s study (2006) also found that those using MA were younger than non-users. In 
addition, the authors controlled for drug trade involvement, and still found a significant 
relationship between MA and aggression. This provided a good argument for a biological 
cause for the link. Further support comes from Sekine et al’s study (2006) which also 
controlled for other substance abuse and also found an association between aggression and 
MA. It is clear from the literature that aggression is associated with chronic abuse resulting in 
paranoia and psychosis where the intentions of others are misinterpreted.  
The media play an influential role in portraying the perceived conclusive causal link 
between MA, aggression and violence (Sheriden et al., 2006; Tyner & Fremouw, 2008). 
Although there is overwhelming and compelling evidence for the relationship between MA 
and aggression, the exact nature of this relationship is still poorly understood (Tyner & 
Fremouw, 2008) and most researchers agree that although biology plays a role, the 
relationship is too complex to simply imply one cause.  
Most of the results of studies supporting this relationship between MA and aggression 
describe the effects of chronic use of MA and aggression, and involved both human and 
animal subjects, with less interest in examining acute administration (Austin, 2004; Brecht et 
al., 2004; Butler et al., 2009; Hall et al., 1996;  Homer et al., 2008; Miczek & O’Donnell, 
1978; Miura et al., 2006; Richards, et al., 1999; Sekine et al., 2006; Sokolov & Cadet., 2006; 
Sokolov, et al., 2004; Volkow et al., 2001; Vorhees, Reed, Morford, Fukumura, Wood, 
Brown, et al., 2005; Wilkins et al., 2009; Zweben, Cohen, Christian, Galloway, Salinardi, 
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Parent, et al., 2004). The studies that do investigate acute doses are inconsistent in their 
findings. While Crowley (1972) did find that rats administered MA were more aggressive, it 
is questionable whether this study was in fact an acute study because the rats were 
administered MA every three days over a period of weeks. In contrast, other studies using 
animals did not support aggression resulting from an acute dose of MA when they compared 
acute with chronic administration (Miczek & O’Donnell, 1978; Richardson, Karczmar & 
Scudder, 1972; Sokolov, et al., 2004; Sokolov & Cadet, 2006). It is agreed that an acute dose 
may enhance a person towards acting aggressively if they are provoked, or in association 
with other conditions (McKetin et al., 2006; Sheriden et al., 2006). This may relate into 
affective defence where aggression is performed due to a perceived threat on territory, or a 
mate. One argument is that aggression does occur in a dose dependent manner, that is, the 
higher the dose, the more chance of aggression (Miczek & O’Donnell, 1978; Tyner & 
Fremouw, 2008). 
 
1.6.4 Crime 
Under the Misuse of Drugs Act, 1975, MA has been classified as a Class A, or schedule 
1 drug in New Zealand since 2003 (Ministry of Health, 1975). To be classed in this category, 
which also includes cocaine and heroin, a drug must be deemed to be a very high risk of 
harm, and is illegal (Ministry of Health, 1975). 
When examining New Zealand’s association with MA and its resulting influence on 
aggressive and criminal behaviour, one survey (Wilkins, Rose, Trappitt,  Sellman, Adamson, 
DeZwart, 2004) arrived at the following conclusions: 1) There is an increased number of MA 
users coming to the attention of Police and drug treatment, 2) Methamphetamine’s easier 
availability has resulted in a greater cross section of society now using it, 3) there is an 
increase in marketing of MA to lower socio-economic groups, and 4) there is an increase in 
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violence associated with its use (including serious and domestic violence). These conclusions 
were derived from information supplied by drug enforcement key informants, and drug 
treatment key informants. Both groups noticed a significant number of younger people now 
using MA (33-46 % agreement). Up to 73 % noticed more serious and violent crime being 
associated with its use, while 85 % noticed a general change in violence associated with its 
use. Over the last five years statistics from New Zealand have shown a similar trend in the 
increased use of MA and its relationship to an increase in crime and violence involving 
aggression. Statistics from 2006 showed that non-cannabis drug offences (including MA) 
more than doubled from 4 per 10,000 in 1996 to 10 per 10,000 in 2005. After this peak, there 
is the acknowledged levelling out with statistics from 2009 showing 4 per 10,000. Drug and 
anti-social offences in 2005 equalled 12.7 % of all recorded offences, and the major 
contributor to the growing non-cannabis related drug offences was possession of 
MA/amphetamine, and their utensils for use. The survey also said the New Zealand police 
had noted a switch in the drug market from cannabis to MA and other drugs (STANZ, 2006). 
A 2007 study involving people recently apprehended and detained in watch houses that 
participated in a programme that measured drug and alcohol use, reported that 44 % said they 
had used MA, and 33.6 % cited it as the worst drug for making them angrier (Hales & 
Manser, 2007). 
The most recent statistics support this trend for both MA and the more pure form of 
crystal MA (Ice) and even though the number of clandestine MA laboratories that have been 
dismantled by Police has risen from five in 1999 to 133 in 2008, evidence suggests a 
levelling out of MA use, following a consistent increase over the last ten years (New Zealand 
Police, 2009; Wilkins et al., 2009). Data from the New Zealand Police Illicit Drug Strategy to 
2010 show that illicit drugs, including MA now cost New Zealand up to 1.31 billion per year 
through aspects such as Police time and hospitalisations. MA users that were part of this 
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study reported spending more money on MA than any other drug, and that they were more 
likely to pay for this with criminal activity, as well as being more likely to access mental 
health services as a result of their use (New Zealand Police 2009; Wilkins, et al., 2009). One 
key consequence of this increased expenditure was the fact that money spent on drugs is not 
available for food, housing, or education, and is therefore a drug related harm. In 2005, MA 
and Ice were considered extremely risky to purchase compared with other substances 
(Wilkens, et al., 2005). 
 Findings from the Illicit Drug Monitoring System (IDMS) support this issue of 
increasing cost, and criminal activity resulting from it, by reporting that the price of MA has 
risen from 2006, causing more problems paying for it. This study reported that the median 
price of a gram of MA is now $700 compared to $610 in 2006, and that a median spendature 
on a single occasion is now $200 (Wilkins et al., 2009). The same study reported that 48% of 
users interviewed said it was now easier to obtain MA, with 62% saying they had purchased 
it from a drug dealer, and 42% from a gang member or associate. This would provide 
evidence for both systemic and economic compulsive violence and aggression to occur along 
side psychopharmacological aggression. Further evidence for the association of MA use with 
aggression and crime is that those users spending more than $1000 per month, committed 
2367 more property crime than others who did not buy MA (Wilkins, et al., 2009). 
In regards to adolescent or youth using MA and committing crime, findings from the 
IDMS show that 13 was the mean age for Users of MA associated with truancy from school, 
and 45% of users had been suspended from school, with the main reason of suspension being 
fighting for 40%. Youth also cited MA use as being highly associated with expulsion from 
school, committing property crime and selling of drugs as ways to make money and pay for 
their habits. In relation to violent crime, 42% had committed a violent crime, and the mean 
age for their first offence was just 17 years of age. Six percent of these youth had committed 
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a violent crime in the past month, with a mean age of 17 as age of first violent offence.  This 
study also showed that there was increased Police contact through both anti-social behaviour 
and criminal activity to pay for the drugs, and in the past 12 months, 18% had been arrested 
for a violent crime (Wilkins, et al., 2009). 
 
1.7 1-Benzylpiperazine (BZP) 
Originally synthesised for use as an anti-parasitic agent to treat infestations of large 
roundworms and pinworms (Gee & Fountain, 2007), 1-benzylpiperazine (BZP) is a 
piperazine derivative which comes as either a hydrochloride salt or a free base.  Unlike 
countries such as the USA, Japan and Australia, it was not until 18th July 2008 that New 
Zealand followed suit and passed legislation which placed BZP into Class C of the New 
Zealand Misuse of Drugs Act 1975, making the selling of it illegal. Research since that time 
has shown that the prohibition of BZP has had a negative impact on both its use and 
availability, with it now being more difficult to obtain and having a higher purchase price in 
2008 compared with 2007 (Wilkins et al., 2009).  
Because of the known risks associated with the use of MA, people sought a safer 
alternative, and BZP is often perceived as a safer option (Aitchison & Hughes 2006; 
Baumann et al., 2005; Brennan, Johnstone, Fitzmaurice, Lea, & Schenk, 2007). Recreational 
drug users as well as people such as truck drivers who wish to stay awake longer and have 
increased energy, are likely to use BZP as a safer alternative to MA (Gee, Richardson, 
Woltersdorf, & Moore, 2005; Johnstone, Lea, Brennan, Schenk, Kennedy,  Fitzmaurice, 
2007).  Research on BZP has shown that the psychotropic effects on behaviour and 
neurochemistry may be indistinguishable from amphetamines (Aitchison & Hughes, 2006; 
Alansari & Hamilton, 2006; Baumann, et al., 2005; Brennan, et al., 2007; Herbert & Hughes, 
2009). Both substances share stimulant properties that produce the euphoric effects associated 
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with recreational drugs of abuse, and both affect DA and 5-HT levels in the CNS (Baumann, 
et al., 2005: Fantegrossi, Winger, Woods, Woolverton, & Coop, 2005; Gee et al., 2005; Gee 
& Fountain, 2007; Herbert & Hughes, 2006; Johnstone et al., 2007). Fantegrossi’s (2005) 
study involving rhesus monkeys, also supports the likelihood of BZP being addictive in a 
similar fashion to MA and cocaine through the fact rhesus monkeys self-administered BZP at 
a similar rate to cocaine. Johnstone et al. (2007) state that an increase in dopaminergic 
neurotransmission underlies much of the behaviour exhibited by rats that have been 
administered BZP. They also state that the effects were similar to those seen after MA 
administration (Gee et al., 2005). This study showed patients admitted to hospital developed 
some adverse reactions up to 24 hours after ingestion of BZP, and concluded that there is a 
narrow safety margin for some users due to aspects such as intrinsic pharmacodynamic 
properties. They also reported that since 2004 when BZP became better known and 
accessible, emergency departments noticed a rapid increase in patients who presented with 
BZP toxicity, which included heart palpitations, agitation, nausea and vomiting. Gee et al. 
(2005) also state that there have been numerous reports of BZP causing either a toxic 
paranoid psychosis or exacerbating an existing mental illness. As does much of the research 
on BZP, this study made no mention of examining acute doses in comparison to chronic use. 
Most cases in this study used varying amounts of BZP and it was not stipulated whether they 
were chronic users. It was concluded that most patients took multiple doses because the first 
dose did not produce desired effects immediately, implying the possibility of increased doses 
and abuse potential. 
Because the research on BZP is limited, especially in relation to the effects of acute 
doses which has no empirical data to date (Aitchison & Hughes, 2006), researchers have 
emphasised the need and importance of further investigations of BZP’s acute behavioural 
effects (especially involving DA) in order to help better understand its functioning (Aitchison 
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& Hughes, 2006; Baumann et al., 2005; Johnstone et al., 2007). By combining BZP with MA 
in research may provide a better understanding of the similarities or differences of these two 
drugs, especially in relation to causing aggressive behaviour. 
 
 
2.0 Aims and Hypotheses of this Study 
 
The aim of this current study was to examine whether an acute dose of either MA or 
BZP will result in aggressive behaviour in adolescence. This question has been largely 
ignored in much of the research to date, with most of the literature concentrating on chronic 
use resulting in paranoid psychosis and dysfunction in mood through the effects on DA and 
5-HT in adults. There appears to be minimal research examining whether a single dose of 
either drug will invoke the radical behavioural changes that the media is so intent on 
portraying as fact.  
Because of the many ethical and practical considerations of using human subjects in a 
study such as this, and the complexity and multi dimensional nature of aggressive behaviour,  
an animal model of aggression was chosen and has support throughout the literature 
(McEllistrem, 2004; Sokolov & Cadet, 2006; Sokolov et al., 2004). The research states that 
although it has been a daunting task using animal models to explain pathological aggression, 
the developmental stage of adolescence is not uniquely human, with similarities across many 
species including the rat, which show adolescent-typical behavioural patterns. These across-
species similarities in behavioural and physiological attributes of adolescence provide 
acceptable face and construct validity for the use of animal models when studying the 
potential neurotoxic effects during adolescence (Spear, 2007b). Weinshenker & Siegal (2002) 
support this view by stating that the neural basis of aggressive behaviour in animals does 
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indeed parallel those observed in humans. Volkow et al. (2001) believe that because animal 
studies have shown MA to be neurotoxic, there should be concern over whether this equates 
to humans.  
The mixed results thus far in animal research on aggression and MA can be the result of 
the different animals and conditions used for each piece of research. Rats are often used, as 
well as cats and mice. What the researchers do agree upon is that there is promising evidence 
for this relationship from the use of animal models (Sokolov & Cadet, 2006). 
Because of the inconsistencies in the research and the neglect of a single acute dose of 
either drug, this study investigated whether or not aggression will result from an acute dose of 
either MA or BZP in adolescence. 
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3.0 Method 
3.1 Subjects 
The subjects were 90 male and 60 female PVG/C hooded rats aged 41 to 50 postnatal 
days (PND), bred in the Animal Facility of the Department of Psychology, University of 
Canterbury. The average weight of the pups during testing was 131.7 grams, with the lightest 
pup weighing 104 grams and the heaviest being 170 grams. When 30 days old, all pups were 
weaned and housed in 525 x 330 x 230mm plastic cages. Sixty of the male pups were housed 
with a female pup, whilst the remaining 30 male pups were housed with up to four pups. The 
focal male rat was housed with a female in an effort to increase the rat’s perception of its own 
territory that it would need to defend against when intruded upon (Malkesman, Maayan, 
Weizman, & Weller, 2006; Weinshenker & Siegal, 2002). In addition, the cage would have a 
female scent in it when the intruder rat was introduced, again possibly increasing the chance 
of aggressive responses occurring through sex-related aggression where sexual arousal can 
increase levels of hostility (Weinshenker & Siegal, 2002). Subjects were housed in a 
controlled environment, with a constant temperature of 20± 1 ºC, a 12 hour light/dark cycle 
(lights came on at 8am), and ad libitum food and water. All subjects were treated in 
accordance with the guidelines set by the Australian and New Zealand Council for the Care 
of Animals in Research and Teaching, and the Animal Ethics Committee of the University of 
Canterbury approved all procedures (see Appendix A). 
 
3.2 Apparatus 
This study utilized the empirically supported resident/intruder test of aggression. This 
test has been cited as a good measure of affective defence, or territorial aggression that 
provides a classical demonstration of motivation to be aggressive that results from the 
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perceived threat from another organism, as well as the perception of having to protect its own 
territory (Weinshenker & Siegal, 2002), and used successively by many previous researchers 
(Johns & Noonan, 1995; Miczek, & O’Donnell, 1978; Sgoifo, De Boer, Haller & Koolhas, 
1996; Sokolov, & Cadet, 2006). It involves recording behaviour in the subject’s home cage, 
which in the present study measured 525 x 330 x 230mm. Since its occupation following 
weaning, the floor of the cage had been covered with absorbent wooden pellets.  For all 
experimental observations, the cage sat on a 700mm high table under a video camera 
mounted in a wooden arm 800mm above the cage. The experimental room was evenly 
illuminated by dim, overhead fluorescent lighting.  
 
3.3 Drugs and Rationale for Doses 
3.3.1 Methamphetamine  
MA was donated as a pure crystal form of the drug by Environmental Science & 
Research Limited (ESR, Wellington, New Zealand). The MA was crushed and then dissolved 
in 0.9% saline to provide High and Low doses of 1 and 2 mg/kg respectively. Previous 
research states that the lowest dose of MA capable of invoking release of dopamine (DA) and 
serotonin (5-HT), which is required to illicit aggressive responses, is 1mg/kg (Baumann et al., 
2005; Brennan et al., 2007; Hughes & Grieg, 1976). Because of this, this study used this dose 
as its minimum dosage, and 2mg/kg as a comparison dosage. 
 
3.3.2 1-Benzylpiperazine  
BZP was purchased from ABRC Gmbh & Co, Karlesruhe, Germany. This was diluted 
in 0.9% saline to provide High and Low doses of 10mg/kg and 20mg/kg respectively. 
Because MA is reported to be ten times stronger than BZP, these doses were adopted to 
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achieve similar levels of potency to 1 and 2 mg/kg MA, as has typified previous research 
(Campbell, Cline, Evans, Lloyd, & Peck, 1973; Gee, et al., 2005; Herbert & Hughes, 2009; 
Johnstone et al., 2007; Wilkins et al., 2009). 
 
3.4 General Procedure 
On Post Natal Days (PND) 41-50, 60 male rats were randomly assigned to five 
experimental groups that were injected with saline (control), 10.0 mg/kg or 20.0 mg/kg BZP, 
or 1.0 mg/kg or 2.0 mg/kg of MA. This periadolescent age is equivalent to adolescence in 
humans (Smith, 2003; Spear, 2007a), when the brain is in a state of transition, both 
anatomically, and neurochemically. This is especially so for the prefrontal and limbic areas 
and systems operated by DA and 5-HT (Aitchison & Hughes, 2006: Vorhees et al., 2005). 
Drug use during this age has been shown to result in long-term changes to the developing 
brain. The brain of an adolescent may respond differently than at other ages to the influence 
of a substance, and it is during this age that drug use often begins (Vorhees et al., 2005).  
One hour before testing, the female was removed from the cage, along with food and 
water. This was done in an attempt to increase the irritability, anxiety or emotionality of the 
resident rat, and thus increase the possibility of aggression as a reaction to this elevated 
anxiety or emotionality. This would incorporate the aforementioned irritable type of 
aggression (Weinshenker & Siegal, 2002). Twenty minutes prior to testing each rat was 
interperitoneally injected with the appropriate drug or saline. Following this delay, an 
intruder rat was placed in the cage with the resident rat for exactly ten minutes.  
Aggressiveness was recorded by noting the occurrence of certain responses on a 
prepared data sheet (Appendix B). The main measure of aggression was the ‘latency time to 
attack’ (LTA) the intruder by the resident rat, and was defined as the “first instance 
(measured in seconds) of movement by the focal/resident rat towards the stimulus/intruder 
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rat at a distance greater than the length of a rat, resulting in near or actual contact”, and 
involved ‘Aggressive Posture’, defined as “the focal rat restraining the intruder rat with 
their front paws, either holding down the other rat or up on hind legs “boxing” with other 
rat”. 
When it became apparent that neither of these responses were the first instance of 
contact, another measure of ‘General/Non-Aggressive Contact’ was utilised. If either of the 
previous two responses occurred following this initial contact then they were recorded as a 
“frequency of occurrence” response, not as a LTA. ‘General/Non-Aggressive Contact’ was 
defined as simply the first move resulting in near contact or contact not involving the 
aforementioned responses. This was measured manually with a stopwatch by the observer in 
seconds because in most instances this was the first contact made by the resident rat. This 
measure was included to determine if the drug had any effect on the resident rat’s speed of 
approaching the intruder which could have been dependent on aggressiveness or 
confrontation-related anxiety.  
Also recorded were the frequencies of the following responses associated with 
aggression (Johns & Noonan, 1995; Malkesman et al., 2006; Weinshenker & Siegal, 2002). 
· Chase – any pursuit of the stimulus/intruder rat around the cage by the 
focal/resident rat. Occurrence of the behaviour stops as soon as the focal rat stops 
moving, or contact is made (does not include first contact as mentioned above). The 
resident rat must chase the intruder rat over a distance equivalent to the length of a rat 
and must include the intruder rat moving away from the resident rat. 
· Sniffing - any aggressive sniffing by the resident rat of the anal/genital region 
(this may/may not include use of paws) of the intruder rat. The behaviour is deemed to 
have stopped when the sniffing stops for 1 second. 
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· Alert position - the resident rat exhibits a sudden interruption of all movement 
with its head directed towards the intruder rat. It must be perfectly still for at least 1 
second duration, and must be facing the intruder rat, not upwards or to the side. 
· Self-groom - the resident rat grooms itself by licking body fur and/or face 
washing (most often after a fight attack). The response is regarded as having ceased 
whenever the grooming stops for more than 1 second. 
· Avoidance - any move greater than the length of a rat that the resident rat 
makes to escape or distance itself from the intruder rat. The response is regarded as 
having ceased when movement stops for more than 1 second. 
· Standing on Hind legs - any instance when the resident rat stands up on its 
hind legs and faces the intruder rat. This does not include standing up to look out of the 
top of the cage. It DOES NOT include contact with the intruder. 
 
3.5 Statistical Analyses 
All raw data was analysed with one-way analysis of variance (ANOVAs) using the 
Statview statistical programme and presented in graphical form as means ± S.E.Ms (see 
Figures 1-8).  For each aggressive behaviour, a one-way ANOVA was performed for each 
drug separately to determine the effects of the two dose levels in comparison with the saline 
condition. Because equivalent potency of the two drugs at each dose level could not be 
ensured, they were each separately compared with the common saline group (in accord with 
previous practice, Herbert & Hughes, 2009). When a significant dose effect occurred, post 
hoc comparisons were made by means of Scheffe tests. 
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4.0 Results 
4.1 Aggressive Posture 
As shown in Figure 1 below, control rats (administered saline solution) restrained the 
intruder rat with their front paws, by either holding down the other rat or up on hind legs, 
boxing, significantly more often than rats administered each dose of both MA, F(2,33) = 
10.44, p<.001, and BZP, F(2,33) = 9.48, p<.001.  There was no significant difference 
between the two dose levels for either drug. 
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Figure 1. Means ± S.E.Ms aggressive posture scores following treatment with saline 
(n=12), 10mg/kg 1-benzylpiperazine (BZP, n=12, low dose) or 1mg/kg methamphetamine (MA, 
n=12, low dose), or 20mg/kg1-benzylpiperazine (BZP, n=12, high dose) or 2mg/kg 
methamphetamine (MA, n=12, high dose). * Significantly different from the saline group. 
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4.2 General/Non-Aggressive Contact 
For both MA and BZP, even though both doses produced shorter latencies to approach 
the intruder rat, the difference was not significant for either drug in comparison to the saline 
group, MA, F(2,33) = 2.25, p = .1338, BZP, F(2,33) = 2.14, p =.1212 (see Figure 2 below). 
This was most likely due to the high variability of the control group as shown by its large 
SEM (± 55.18).  
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Figure 2. Means ± S.E.Ms general/non-aggressive contact scores measured as a latency 
time to attack in seconds following treatment with saline (n=12), 10mg/kg 1-benzylpiperazine 
(BZP, n=12, low dose) or 1mg/kg methamphetamine (MA, n=12, low dose), or 20mg/kg1-
benzylpiperazine (BZP, n=12, high dose) or 2mg/kg methamphetamine (MA, n=12, high dose). 
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4.3 Chase 
Rats administered saline chased the intruder rat significantly more often than rats 
administered either MA, F(2,33) = 7.52, p<.01, or BZP, F(2,33) = 8.36, p<.01. There were no 
significant differences between the two doses for either drug (see Figure 3 below). 
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Figure 3. Means ± S.E.Ms chase scores following treatment with saline (n=12), 10mg/kg 1-
benzylpiperazine (BZP, n=12, low dose) or 1mg/kg methamphetamine (MA, n=12, low dose), or 
20mg/kg1-benzylpiperazine (BZP, n=12, high dose) or 2mg/kg methamphetamine (MA, n=12, 
high dose). * Significantly different from the saline group. 
 
4.4 Sniffing 
Rats administered saline sniffed the intruder rat significantly more often than those 
administered either MA, F(2,33) = 14.99, p<.001, or BZP, F(2,33) = 12.31, p<.001. For rats 
administered MA there was no difference between doses for the frequency of sniffing.  
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However, for rats treated with BZP, the higher dose resulted in significantly more sniffing of 
the intruder rat by the resident rat (see Figure 4 below). 
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Figure 4. Means ± S.E.Ms sniffing scores following treatment with saline (n=12), 10mg/kg 
1-benzylpiperazine (BZP, n=12, low dose) or 1mg/kg methamphetamine (MA, n=12, low dose), 
or 20mg/kg1-benzylpiperazine (BZP, n=12, high dose) or 2mg/kg methamphetamine (MA, n=12, 
high dose). * Significantly different from the saline group. 
 
4.5 Alert Position 
Rats treated with MA were marginally significantly affected in adoption of the Alert 
Position, F(2,33) = 3.16, p =.055. This arose from a significant difference between the saline 
and the Low dose, but not the High dose group.   Adoption of the Alert Position was 
significantly affected by BZP, F(2,33) = 6.20, p<.01, and interestingly, similar to MA,  only 
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the Low dose resulted in a significantly higher frequency of the response. The difference 
between the low and the high dose of BZP was significant (see Figure 5 below). 
 
 
Figure 5. Means ± S.E.Ms alert position scores following treatment with saline (n=12), 
10mg/kg 1-benzylpiperazine (BZP, n=12, low dose) or 1mg/kg methamphetamine (MA, n=12, 
low dose), or 20mg/kg1-benzylpiperazine (BZP, n=12, high dose) or 2mg/kg methamphetamine 
(MA, n=12, high dose). * Significantly different from the saline group. 
 
4.6 Self-Grooming 
Rats treated with both MA and BZP displayed significantly less self-grooming than 
those treated with saline, MA, F(2,33) = 5.16, p<.05, BZP, F(2,33) = 4.11, p<.05. 
Differences between the two dose levels were not significant for either drug (see Figure 6 
below). 
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Figure 6. Means ± S.E.Ms self-grooming scores following treatment with saline (n=12), 
10mg/kg 1-benzylpiperazine (BZP, n=12, low dose) or 1mg/kg methamphetamine (MA, n=12, 
low dose), or 20mg/kg1-benzylpiperazine (BZP, n=12, high dose) or 2mg/kg methamphetamine 
(MA, n=12, high dose). * Significantly different from the saline group 
 
4.7 Avoidance 
Rats treated with MA avoided the intruder rat significantly more often than rats in the 
saline group, F(2,33) = 5.05, p<.05. There was no significant difference between the two 
doses. No significant effect occurred for rats treated with BZP, F(2.33) =.04, p =.9649 (see 
Figure 7 below).  Differences between MA- and BZP- treated rats were significant for both 
dose levels of each drug i.e., level 1, t(22) = 4.31,  p >.001; level 2, t(22) = 2.57. p <.05 
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Figure 7. Means ± S.E.Ms avoidance scores following treatment with saline (n=12), 
10mg/kg 1-benzylpiperazine (BZP, n=12, low dose) or 1mg/kg methamphetamine (MA, n=12, 
low dose), or 20mg/kg1-benzylpiperazine (BZP, n=12, high dose) or 2mg/kg methamphetamine 
(MA, n=12, high dose). * Significantly different from the saline group. # Significantly different 
from the other drug group for the same dose level. 
 
4.8 Up on Hind Legs 
Rats administered MA reared up on their hind legs significantly more often than those 
administered saline, F(2,33) = 6.67, p<.01. There was no significant difference between the 
two doses. There was also a significant effect of BZP on this response, F(2,33) = 3.55, p<.05, 
but only the ‘Low’ dose produced a significantly higher frequency than that shown by saline-
treated rats. Rats treated with 2 mg/kg MA displayed this response significantly more often 
than rats treated with 20 mg/kg BZP, t(22) = 2.23. p <.05, but there was no significant 
*
*
1
2
3
4
5
6
7
8
9
10
Saline 1 2
Dose level
Fr
eq
ue
nc
y 
of
 o
cc
ur
en
ce
MA
BZP
# 
# 
 43
difference between the two drugs at the lower dose level, t(22) = 1.33, p >.1 (see Figure 8 
below).  
 
 
Figure 8. Means ± S.E.Ms up on hind legs scores following treatment with saline (n=12), 
10mg/kg 1-benzylpiperazine (BZP, n=12, low dose) or 1mg/kg methamphetamine (MA, n=12, 
low dose), or 20mg/kg1-benzylpiperazine (BZP, n=12, high dose) or 2mg/kg methamphetamine 
(MA, n=12, high dose). * Significantly different from the saline group. # Significantly different 
from the other drug group for the same dose level. 
For a full display of means and S.E.Ms for all eight behavioural measures, please see 
Appendix C. 
 
4.9 Comparative Summary of all Drug Effects 
Table 1 below provides a summary of all the results described above. From inspection 
of the table, it is clear that both drugs had similar effects on all measures of aggression, 
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showing either no significant difference from the saline group, or a decrease in the aggressive 
behaviour. The exceptions to this were the ‘avoidance’ and ‘alert position’ responses which 
resulted in an increase in both cases in comparison to the saline group in at least one of the 
doses. 
 
Table 1 
Summary of the Behavioural Effects of Methamphetamine and 1-Benzylpiperazine in 
Comparison to a Saline Group 
Measure/Behaviour Behavioural Effect  
 MA BZP  
Aggressive Posture Decreased by 
both doses 
Decreased by 
both doses 
 
General/Non-
Aggressive Contact 
No effect No effect  
Chase Decreased by 
both doses 
Decreased by 
both doses 
 
Sniffing 
 
Decreased by 
both doses 
Decreased by 
both doses 
 
Alert Position 
 
Increased by 
lower dose 
Increased by 
lower dose 
 
Self-Grooming 
 
Decreased by 
both doses 
Decreased by 
both doses 
 
Avoidance 
 
Increased by 
both doses 
No effect  
Up on Hind Legs 
 
Increased by 
both doses 
Increased by 
Lower dose 
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5.0 Discussion 
The popular media portrays MA as a drug that will cause addiction with a single 
dose, and adverse effects will follow, such as aggressive behaviour. Research on MA and 
BZP provides little evidence for this. The aim of this study was to examine if an acute dose of 
either MA or BZP would result in increased aggression. This study randomly assigned 60 
adolescent rats, aged between post natal days (PND) 41 to 50 to either a saline group, or a 
Low (1mg/kg MA or 10mg/kg BZP) and High (2mg/kg MA or 20mg/kg BZP) dose group. 
Each rat was then exposed to the well-established resident/intruder test of aggression (Johns 
& Noonan, 1995; Miczek, & O’Donnell, 1978; Sgoifo et al., 1996; Sokolov, & Cadet, 2006; 
Weinshenker & Siegal, 2002). Aggression was assessed by means of eight previously used 
behavioural measures (Aggressive Posture, General/Non-Aggressive Contact, Chase, 
Sniffing, Alert Position, Self-Groom, Avoidance, and Standing on Hind legs). 
 
5.1 Summary of Results 
Overall, the results showed that rats administered either MA or BZP, at both low and 
high doses, displayed less aggressive behaviour than control rats administered saline. The 
exceptions to this were for measures involving anxiety or fear, or psychomotor agitation, 
which have been shown to be increased by MA and BZP in previous research (Cancela, et al., 
2001; He, et al., 2005; Herbert & Hughes, 2009). These anxiety-related behaviours may be 
associated with aggressive tendencies, through factors such as heightened states of arousal, 
increased energy and the tendency to perform risky behaviours (Boles and Miotto, 2003; 
Cancela et al., 2001; He et al., 2005; London et al., 2004). The overall non-aggressiveness of 
the drug-treated rats was also supported by the fact that the initial main aggressive behaviour 
measures of Latency Time to Attack, and Attack Posture were not actually the first instances 
of contact as observed in other research using this test of aggression (Johns & Noonan, 1995; 
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Miczek, & O’Donnell, 1978; Sgoifo et al., 1996; Sokolov, & Cadet, 2006).  Because of this, 
another latency time measure was implemented. This was the General/Non-Aggressive 
Contact measure, which was actually a latency to approach measure instead of an actual 
aggressive attack. This measure was included to determine if the drug had any effect on the 
resident rat’s speed of approaching the intruder which could have been dependent on either 
aggressiveness or confrontation-related anxiety. 
 
5.1.1 Aggressive Posture 
Results from this behavioural measure indicated that an acute dose of either MA or 
BZP did not increase aggressive behaviour. Control rats administered saline restrained the 
intruder rat with their front paws, by either holding it down or by up on hind legs boxing with 
it, significantly more often than rats administered either MA or BZP. This significant 
difference was consistent for both high and low doses of each drug. For both drugs there was 
no significant difference in aggression between dose levels meaning it made little difference 
whether the rat was administered the low or high dose of either drug. When compared with 
the control group, both doses of the two drugs showed very similar patterns of effects across 
comparative doses (high versus high, and low versus low, as illustrated by their graphical 
representations).  
This lack of aggression displayed by rats administered either MA or BZP compared to 
saline treated rats may be a result of the immediate intoxication effects associated with these 
substances, namely, the novelty of the experience because of no previous exposure to the 
drugs. These effects include a euphoric high and pleasure experienced by the rats from their 
first exposure to these stimulant drugs (Boles & Miotto, 2003; Carlson, 2004; Julien, 2001), 
and are components of Hoaken and Stewart’s (2003) pharmacological effects of intoxication. 
This would be in comparison to the aggressive behaviours resulting from the adverse and 
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unpleasant emotions resulting from psychosis and paranoia associated with chronic use, and 
the acknowledged changes in monoamine functioning. This would provide support for the 
view that it is only chronic use that causes aggression through changes in monoamine 
functioning (Boles & Miotto, 2003; Homer et al., 2008; McKetin et al., 2006; Sekine et al., 
2006).   
 
5.1.2 General/Non-Aggressive Contact 
Although there was no significant effect for either drug in comparison to the control 
group, from casual inspection of Figure 2, rats administered both doses of either MA or BZP 
may have appeared to approach the intruder rat more quickly than control rats.  Although the 
non-significant outcome could have resulted from the high variability amongst saline-treated 
rats (SEM = 55.18 versus 5.30 and 4.48, and 11.14 and 2.57 for each dose of MA and BZP 
respectively), repeating the ANOVAs after removing two outlying control rats with 
extremely long approach latencies (401 and 602 seconds) still did not result in a significant 
effect for either drug i.e., saline = 25.63 ± 6.87, low dose MA = 19.46 ± 5.30, high dose MA 
= 23.73 ± 4.48 (F2,31 = 0.33, p = .723), low dose BZP = 36.03 ± 11.14, high dose BZP = 
13.65 ± 2.57 (F2,31 = 2.17, p = .1312).  It is therefore abundantly clear that neither drug 
affected this measure. 
 
5.1.3 Chase 
Treatment with each dose of MA or BZP reduced the number of times the rats chased 
each other and hence their aggressiveness. As with the previous two aggression measures 
there was no significant difference between the two dose levels for either drug. 
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5.1.4 Sniffing 
Both doses of each drug significantly reduced sniffing thereby providing further 
support for the control rats being more aggressive. Of interest, because BZP is considered a 
milder drug than MA, the high dose of BZP resulted in the most sniffing for the four doses 
and was significantly greater than the low dose of BZP. This high dose of BZP was not 
significantly different from either dose of MA, and was very similar to the 1mg/kg dose of 
MA. This may provide further evidence for the doses of each drug being comparable, as 
shown in past research (Campbell et al., 1973; Gee, et al., 2005; Herbert & Hughes, 2009; 
Johnstone et al., 2007; Wilkins et al., 2009). Contrary to most other responses (except 
avoidance described below), the two drugs did not follow a similar dose-related trend. This 
implies that rats treated with a high dose of BZP were more inclined to approach and 
investigate the intruder rat, showing less anxiety, but not evoking aggression. 
 
5.1.5 Alert Position 
For this behaviour there was a significant increase in rats administered a drug in 
comparison to control animals. Those administered a low dose of both drugs adopted this 
position significantly more often than control rats. Although this behaviour is regarded as an 
aggressive response, it may reflect a slight elevation in anxiety rather than aggressiveness. 
This could be due to the fact anxiety involves the fight or flight response which can include 
freezing (Craske & Barlow, 2008), and is supported by research reporting an increase in 
anxiety in rats administered MA and BZP (Aitchison, & Hughes, 2006; Cancela, et al., 2001; 
He, et al., 2005; Herbert & Hughes, 2009; London et al., 2004). A rat adopting the alert 
position may involve some fear- or anxiety-related freezing in response to a perceived threat 
from an intruder. Increased anxiety and the fight or flight response, has been associated with 
changes in mood and a heightened state of arousal, which at extremes may lead to aggressive 
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acts (Cancela, Basso, Martijena, Capriles, & Molina, 2001; He, Xu, Yang & Li, 2005; 
London, Simon, Berman, Mandelkern, Lichtman, Braman, et al., 2004). These aggressive 
acts might arise from the fight mode of responding being deployed for defence. This 
possibility would also support one of Hoaken and Stewarts’ (2003) four physiological effects 
used to conceptualise intoxication (alteration of the psychomotor system; alteration of the 
anxiety and/or threat system; alteration of the pain system; and, alteration of certain higher 
order cognitive capacities), that are likely to increase the chances of aggression. The effect 
involved here is through alteration of higher cognitive capacities. In this lower state of 
arousal these results coincide with other results signifying a reduction in aggression, not the 
apparent increase.  
This increase in alertness for rats treated with either MA or BZP may also relate to the 
aforementioned intoxication symptomology for these two drugs. One of the acknowledged 
maladaptive behavioural or psychological changes associated with intoxication from 
stimulants (which characterised both MA and BZP) is hyper-vigilance (Carlson, 2004). 
Hyper-vigilance would appear similar to the alert position as both behaviours involve the 
constant scanning, or watching of other stimuli in the immediate vicinity of the user. This 
lack of bodily movement is in comparison to control rats that appear more aggressive as they 
move about and attack more often. Because they were not experiencing the intoxication 
effects of either drug, control rats were less likely to remain inactive, as in the alert position. 
 
5.1.6 Self-Grooming 
The results of this behavioural measure also supported control rats being more 
aggressive than rats treated with either MA or BZP. This was evidenced by control rats 
exhibiting significantly more self-grooming in comparison to rats treated with either dose of 
MA or BZP. Again the dose-response profile was similar for both MA and BZP showing very 
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few occasions of self-grooming, thus suggesting less anxiety for these rats compared to 
control rats. These results along with the fact that rats treated with either MA or BZP adopted 
the aggressive posture, chased and sniffed the intruder rat significantly less often than control 
rats implied that less aggressive behaviour was being displayed. 
 
5.1.7 Avoidance 
Rats treated with saline or either dose of BZP did not attempt to avoid the intruder rat 
very often. However, rats treated with both doses of MA avoided the intruder rat significantly 
more often than control rats as well as rats treated with BZP. Although this could imply that 
both doses of MA caused an increase in aggressive behaviour, these results are possibly 
related to a slight increase in anxiety, as was observed for rats adopting the alert position 
behaviour. This increase in anxiety, but not in BZP treated rats across the same dose levels 
has been shown previously in a novel Y-maze (Herbert & Hughes, 2009). This is consistent 
with results from the alert position measure, which taken together may imply increased 
anxiety, but not elevated enough levels to result in aggression. Yet, as stated previously this 
possibility of increased anxiety was not supported by all results. The behavioural measures of 
self-grooming and actual time to approach the intruder rat suggested less anxiety in these 
MA- treated rats. 
 
5.1.8 Up on Hind Legs 
Results for this behaviour were similar to the avoidance and alert measures with an 
increase following administration of both MA and BZP (not for avoidance). This effect 
occurred for both doses of MA, but only for the low dose of BZP. Again, the increase in this 
behaviour may imply increased aggression as a result of being treated with MA or BZP, but 
this increase may have been mediated by other factors. These mediating factors include the 
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aforementioned maladaptive behavioural or psychological changes associated with 
intoxication from these drugs such as hyper-vigilance, psychomotor agitation and increased 
energy (Carlson, 2004; Julien, 2001). The experiencing of these symptoms might result in the 
rats moving about more often and investigating their cage by standing up on their hind legs, 
and being hyper-vigilant on what is occurring around them. This would seem to contradict 
results from the Alert Position behavioural measure where hyper-vigilance may have been 
displayed through the adoption of this position where there is no movement by the rat. Hyper-
vigilance may be expressed in several different ways, of which both rapid scanning of the 
environment and watchfulness while immobile are both behavioural expressions.  
In support of this result not being due to increased aggression is that this measure’s 
outcome is not similar to results from the Aggressive Posture measure. It is possible that this 
response could be a prelude to Aggressive Posture because rats often began in this position 
before fighting or boxing each other (as in Aggressive Posture). If results from this measure 
implied increased aggression, then it would follow that a similar dose-response profile should 
have been observed for the Aggressive Posture measure as well (more occurrences of this 
behaviour for the two drugs). This did not happen because, although both doses of MA 
increased standing up on their hind legs facing each other, this was not so for the Aggressive 
Posture measure. For this latter measure, both doses of MA decreased the behaviour thereby 
indicating opposite effects of MA on these two behaviours.  This of course does not support 
an increase in aggressive behaviour resulting from MA or BZP treatment. In addition, by 
adopting the Alert Position significantly less often than rats treated with either MA or BZP, 
control rats may have been more aggressive towards the resident rat, thus having less time to 
time to freeze in the alert position or to stand up on their hind legs facing the resident rat. 
Consequently, they may have been more inclined to fight whilst in this position. This is a 
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possibility that could be examined in future research by recording behaviours of the intruder 
rat as well. 
 
5.2 Overall Discussion 
Overall, the results do not suggest increased aggression following a single dose of MA 
(or indeed BZP), and thus support previous research that indicates chronic use is required for 
this to happen. This chronic use produces changes in normal neurotransmitter functioning, 
especially for DA and 5-HT through Hoaken and Stewart’s (2003) neurotoxic damage to the 
brain. It is dysfunctioning of these neurotransmitters that results in aggression, especially 
affective defence (Weinshenker & Siegal, 2002) through paranoia and psychosis. It is this fact 
that provides support for a biological mechanism for the link between habitual MA use and 
aggression.  An acute dose does not appear sufficient to produce the amount of change in 
monoamine functioning required for aggression to be evoked. The present results are 
consistent with previous research on acute doses of MA that found no resulting aggression 
(Miczek & O’Donnell, 1978; Richardson et al., 1972; Sokolov, et al., 2004; Sokolov & 
Cadet, 2006), but do not support studies such as that of Crowley (1972) in which aggression 
resulted from an acute dose. Because the present study only used two relatively low doses of 
MA, it is not possible to evaluate the dose dependent view of links between MA and 
aggression, which maintains that, the higher the dose, the greater the likelihood of aggressive 
behaviours occurring (Miczek & O’Donnell, 1978; Tyner & Fremouw, 2008). Of importance 
is that these low levels, in combination with the lack of prolonged and sustained exposure to 
the drugs, may not result in the serious changes and dysfunctioning in DA and 5-HT 
associated with mood changes and aggression.  
Of the eight behavioural measures associated with aggression used in this study, only 
three resulted in a significant increase for rats treated with either MA or BZP (Alert Position, 
 53
Avoidance and Up on Hind Legs). Although, increases in these behaviours might imply 
increased aggression, it is also possible that they were due to effects of stimulant intoxication 
such as hyper-vigilance and higher drug-related anxiety, but not to a level that could result in 
aggressive behaviours. Any such increase in anxiety may be a result of the fight or flight 
mode, but again not to the extent where fighting results. If Alert Position, Avoidance and Up 
on Hind Legs were more indicative of anxiety than aggression, then along with the other 
measures that showed decreases for rats treated with either MA or BZP, the overall trend for 
the study as a whole was reduced drug-related aggression. Hence, the results did not support 
the view often portrayed by the media that a single dose (especially of MA) can result in 
adversely changed behaviour (Sheriden et al., 2006; Tyner & Fremouw, 2008). 
 
5.2.1 Dose Levels/ MA versus BZP 
For rats treated with MA, there were no consistent differences between the two doses in 
their effects.  On the other hand, BZP produce a few differences between doses but one dose 
did not consistently increase or decrease the response more than the other i.e., a low dose of 
BZP resulted in significantly less sniffing of the intruder rat compared to a high dose, yet the 
same dose resulted in Alert Position being adopted significantly more often. 
Although equivalent potency of the two drugs at each dose level could not be assumed, 
it was interesting to examine several differences between the two drugs. Overall, the visual 
presentation of results appeared similar when low and high dose responses were compared to 
saline and the corresponding dose level of the other drug, with no noticeable significant 
difference between drugs for both low and high dose levels. That is, when a low dose of MA 
resulted in a difference from the control group, the low dose of BZP produced a very similar 
result (and the same for high doses of both drugs).  
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 The exceptions to this were results for the Avoidance and Up on Hind Legs measures. 
For both these, the dose-response profiles of the two drugs were qualitatively different from 
each other. For avoidance of the intruder rat, the administration of MA resulted in a 
significant increase in avoidance for both dose levels in comparison to the same level of BZP 
(ie., a low dose of MA versus a low BZP dose). This pattern occurred again for the resident 
rat standing up on its hind legs, with both doses of MA resulting in a significant increase in 
this behaviour compared to saline, but this time only the high dose of MA resulted in a 
significant difference to the high dose of BZP. 
This similarity in patterns of results across both drugs supports previous research 
showing that BZP can result in similar patterns of behaviour to MA (Herbert & Hughes, 
2009). This is also consistent with research showing that BZP’s psychotropic effects on 
behaviour and neurochemistry may be indistinguishable from amphetamines because of their 
similar stimulant properties affecting DA and 5-HT (Aitchison & Hughes, 2006; Alansari & 
Hamilton, 2006; Baumann, et al., 2005; Brennan, et al., 2007; Fantegrossi et al., 2005; Gee et 
al., 2005; Gee & Fountain, 2007; Herbert & Hughes, 2009; Johnstone et al., 2007). This 
would also provide empirical data supporting the fact that BZP is not a safer option than MA. 
 
5.3 Implications and Applications of Results  
The relevance of these results to humans is the possibility that increasing the 
understanding of how these substances may affect human behaviour may help to reduce the 
significant costs associated with their use and abuse, as well as reducing the incorrect 
assumptions about their use. It is acknowledged that adolescence is a time of experimentation 
and that this often incorporates drug use, so a better understanding of how these drugs 
actually affect the user will help guide the diagnosis of a substance abuse problem and its 
treatment in this age group. By dispelling the incorrect assumption that a single use of MA 
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can result in permanent behavioural and psychological changes, the general public will also 
gain a more accurate awareness of the dangers of taking these drugs, especially when 
habitually used. The many adolescents who try these drugs once as part of growing up will be 
able to be better separated from those young people who have serious addiction problems and 
thus require more intensive treatment. 
By adding support to previous research findings that suggest BZP may mirror MA in its 
psychotropic effects, results of the present study help emphasise the risk of exposure to the 
former drug. This will help the public become aware that BZP is not a safer option than better 
recognised ‘hard drugs’ such as MA. This could then result in people making more informed 
decisions when faced with using these drugs, as well as assisting policy makers in their 
efforts to produce laws for their control. Greater control, through an increased understanding 
may help to reduce the aforementioned significant costs to society through their use and 
abuse (Tyner & Fremouw, 2008). 
Understanding that aggression associated with MA use is a result of chronic and not 
acute use can guide research in the study of chronic use, and how this persistent use of these 
drugs actually brings about dysfunctioning of DA and 5-HT. This may help to understand 
how these two neurotransmitters are associated with paranoia and psychosis which is in turn 
associated with aggression.  
Results from this study may also provide information to enable a better understanding 
of the concept of affective defence and the many variations of how and under what 
circumstances it is displayed. This could then help researchers relate this to human examples 
of situations involving this type of aggression, and thus reduce the associated costs. 
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5.4 Limitations of this Study 
There were several limitations to this research that may have influenced results. The 
first of these is the dose levels administered to the rats. Although dose levels used in this 
study are consistent with previous research that shows that 1mg/kg of MA is capable of 
invoking the release of DA and 5-HT required to illicit aggressive behaviours (Baumann et 
al., 2005; Brennan et al., 2007; Crowley, 1972), they may have not been strong enough to 
evoke aggression consistently through changes in DA and 5-HT resulting from toxicity to 
these neurotransmitters. This change in monoamine functioning is required to produce the 
paranoid psychosis associated with aggression (Boles & Miotto, 2003; Julien, 2001). 
However, in earlier studies involving acute doses of up to 7 and 8 mg/kg of MA, increased 
aggression still did not occur (Richards, et al., 1999; Sokolov & Cadet., 2006; Sokolov, et al., 
2004). Addressing this issue of dose level, would also help to establish if there is indeed an 
argument for aggression occurring in a dose dependent manner (Miczek & O’Donnell, 1978; 
Tyner & Fremouw, 2008). 
Another limitation may be the route of administration this study utilised, which was by 
way of intraperitoneal injection. Although MA administered by this route has been related to 
significantly more aggressive behaviour (Hall et al., 1996), substances such as MA and BZP 
are taken in a variety of ways by humans, such as inhalation through smoking, and orally. 
Differences in the rapidity of the onset of drug action could determine whether or not 
aggression results, as has been observed with crack cocaine and its equivalent form of MA, 
Ice (Julien, 2001). An example here is that inhalation through smoking MA results in a 
quicker and more intense effect than injection into the blood stream (Blanchard & Blanchard, 
1999; McKetin et al., 2006).  
Applying results from animal studies to humans may be another limitation of this 
current study. This is because of discrepancies in dose levels of drugs used across all the 
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research. Some researchers question the external validity of animal studies because contrary 
to other psychotropic drugs, lower doses of MA are typically adopted than what humans tend 
to use, resulting in animals having disproportionally lower blood concentration levels of the 
drug in comparison to humans (Tyner & Fremouw, 2008). Yet, in response to this limitation, 
it would be unethical to use humans in a study such as this which would involve participants 
taking illicit substances and then indulging in aggressive behaviours aimed at causing harm to 
another. 
The timing of adolescence was also an area of possible weakness in this research. 
Although research acknowledges that PND 41 to 50 in rats is often regarded as equivalent to 
adolescence in humans (Smith, 2003; Spear, 2007a), there is considerable variation in 
opinions of when exactly adolescence occurs across species and sexes (Spear, 2007b). These 
differences in when adolescence actually occurs can result from individual differences in 
maturity, brain development and temperament. While some will develop these aspects at an 
early age, some may not have equal development until a much later age. These differences 
could then impact on results from behavioural testing by providing large variations in results 
for this age group. This could in turn cause behavioural differences to be attributed to 
manipulated variables (such as drug dose) instead of individual age differences.  
Also of relevance is the breed of rats. The PVG/C hooded rats used in the present study 
are known for their docile nature and low activity in relation to other breeds. Even though 
this may make them easier to handle and a popular breed to use in experimentation, it may 
reduce their natural inclination to be active and aggressive (Animal Research Centre, 2010). 
 
5.5 Strengths of this Study 
Strengths of this study include the utilisation of an empirically supported test of 
aggression. The Resident/Intruder test of aggression has been cited as a good measure of 
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affective defence, or territorial aggression, and has been used successively by many previous 
researchers in combination with the responses recorded in the present study (Johns & 
Noonan, 1995; Miczek, & O’Donnell, 1978; Sgoifo et al., 1996; Sokolov, & Cadet, 2006; 
Weinshenker & Siegal, 2002). In support of this test being a strength for this study is that all 
eight measures used occurred during testing. The fact that often these behaviours were 
performed by both the resident/focal rat, and the intruder rat, show their validity through their 
regular occurrences. An invalid behavioural measure would most likely not have occurred 
very often, and would also not likely have been observed by both focal and intruder rats.  
Purity of drugs is another methodological strength of this study. In real life scenarios it 
is rare to find a pure form of a drug as many recreational drugs are made with ingredients that 
are easy to procure. This is especially relevant for MA which is made in clandestine 
laboratories, and can be synthesised from general household products such as iodine and 
sodium hydroxide found in drain cleaners, and ephedrine and pseudoephedrine which are 
found in over-the-counter cold and flu remedies (McFadden, & Matuszewich, 2007; New 
Zealand Police 2009; Tyner & Fremouw, 2008; Volkow et al., 2001; Wilkins et al., 2009). 
This can result in ‘dirty drugs’ containing many different substances, all of which may have 
different effects on the user (Fergusson et al., 2008). This current study used MA which was 
donated in a pure crystal form by Environmental Science & Research Limited (ESR, 
Wellington, New Zealand), and pure research-grade BZP purchased from ABRC Gmbh & 
Co, Karlesruhe, Germany. This ensured that the drugs used were not contaminated by foreign 
substances thereby ensuring that the results were truly associated with the drug itself and not 
confounded by other ingredients. 
Controlling for other possible confounding factors through the use of an animal model 
of aggression was another strength of this study. This is because the rats used were all housed 
in a contained environment in an animal facility, which allowed other extraneous factors 
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acknowledged to influence the relationship between drug use and aggression in humans to be 
eliminated. Examples of these extraneous factors are childhood exposure to drug use, lack of 
parental control and attachment issues (Chassin, Ritter, Trim, & King, 2003). This again 
enabled the results to be related more precisely to the effects of the drug, and not to other 
factors. Consequently, the results are more likely to be relevant to a biological basis for any 
drug/aggression relationship involving Psychopharmacological Violence rather than Systemic 
or Economic Compulsive Violence (Boles & Miotto, 2003). 
Another strength of this study, related to both purity of drug, and confounding 
factors, is that any resulting aggression, or lack of, could be attributed to the principle use of 
MA or BZP. These drugs are mainly used in conjunction with other drugs such as marijuana, 
and this could determine whether or not aggression develops as a consequence of chronic use 
(Fergusson, et al., 2008). The other drugs being used could affect monoamine functioning as 
well. Because this study guaranteed no previous drug use by the participants, the results were 
attributable only to the action of MA or BZP. 
 
5.6 Suggestions for Future Research 
To address some of the limitations of this study, and to help provide an increased 
understanding of how MA and BZP use is associated with aggression, several initiatives 
could be adopted in future research. Firstly, defaecation frequency of the resident rat could be 
measured to determine if it is more fearful or not, or is in a state of high emotional reactivity 
(Aitchison & Hughes, 2006; Anderson & Hughes, 2008). An increase in numbers of faecal 
boluses has been associated with greater fear and anxiety which in turn can lead an increase 
in aggressiveness as a response to this heightened emotional state.  
In addition, higher doses could be administered to see if aggression does occur in a 
dose-dependent manner thereby enabling determination of the critical dose for the production 
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of aggression through changes in monoamine functioning (quantitative). This would enable 
determination of the toxic levels of MA and BZP which result in the paranoia and psychosis 
associated with chronic use. 
With respect to to the toxicity of chronic use in relation to DA and 5-HT, it would be 
interesting to measure these transmitters after an acute dose, and then subsequently after the 
development of dependence from chronic use, followed by withdrawal when the rat is no 
longer exposed to the drug. This would allow a systematic tracking of the changes in their 
functioning resulting from increased toxicity from the chronic use of these drugs. This in turn 
could provide a better understanding of the level of these drugs needed in the brain to 
produce this toxicity and resulting dysfunctioning in these monoamines. Testing 
aggressiveness during withdrawal, and then after a period of abstinence could help 
researchers observe if the damage to the functioning of the transmitters is reversible through a 
decrease in aggressive behaviour.   
In future research it would be useful to record the responses of the intruder rat because 
in the present study, the intruders often appeared to be more aggressive than the resident rats 
in terms of the frequencies of the responses recorded for the residents. Recording behaviour 
of the intruder as well as the resident rat would provide more information, and sample more 
subtypes of aggression. In doing this, not only would aggressive behaviours associated with 
affective defence be observed (such as inter-male, sex-related and territorial), but predatory 
aggression could also be observed because of an intruder rat’s tendency to be aggressive 
when not protecting its own territory. Observing both the intruder and resident rat could 
provide more information about behaving aggressively while under the influence of 
substances. 
 Including sex differences would also be of interest as a female rat may react differently 
to an intruder in her home cage, especially if she was pregnant or was defending her pups. 
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Inclusion of females would also allow a comparison of sex differences for these drugs, as it is 
likely that both MA and BZP would affect males differently to females, as has been shown in 
previous research on a variety of psychotropic drugs (Hughes, 2007). 
 
5.7 Conclusion 
The results from the present study support the view that an acute dose of either MA or 
BZP will not result in aggression. The association between MA use and aggression is 
acknowledged to result from chronic use resulting in dysfunctioning of the neurotransmitters, 
DA and 5-HT, which in turn leads to paranoia and psychosis through the drug’s toxic effects. 
These neurotransmitters are especially susceptible to the influences of drugs in the adolescent 
years when natural change is occurring, and the experimentation with drugs begins to occur. 
This age group are also associated with a large volume of violent and aggressive crime, 
causing high costs to society.  
Although individual differences mean that there will be an occasional person who 
experiences mood altering properties from an acute dose of MA (Boles & Miotto, 2003), in 
general, an acute dose does not appear to affect these neurotransmitters to the extent that 
changes in aggressive behaviour are apparent. What may result from an acute dose of MA or 
BZP is behaviour associated with experiencing a euphoric high and pleasure from the first 
exposure to these stimulant drugs. This would involve hyper-vigilance, increased alertness 
and psychomotor agitation. As a result of this, instead of increasing aggression, an acute dose 
may in fact reduce the chances of aggressive behaviour through the euphoric high and novel 
experience which supersedes fear or feelings of threat resulting in affective defensive 
aggressive behaviours. Once the user habituates to this and thus requires more drug to get the 
same effect, the aforementioned changes in monoamine functioning combine to cause the 
paranoia and psychosis involved in misinterpreting others intentions and thus aggression. 
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With respect to BZP, it appears that this drug may indeed produce similar effects to 
MA, and thus, is not necessarily a safer option than MA. The possible detrimental effects of 
longer-term use these two drugs can not be ignored, but to date there is no support for such 
effects being caused by a single dose of either drug. 
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Appendix A 
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Appendix B 
 
Group Number: Group Name: 
(eg. 1mg/kg-Methamphetamine-R/I 1st) 
Rat: Test: 
Aggressive 
Behaviour 
Operational Definition   
Latency Time to 
Attack (LTA):  
 
first instance (measured in seconds) of movement by the 
focal/resident rat towards the stimulus/intruder rat of a 
distance greater than the length of a rat, resulting in near or 
actual contact. Includes: 
 
 
 
Frequency 
 
 
 
Extra comments 
Aggressive Posture  
 
 
the focal rat restraining the intruder with front paws, either 
holding down other rat or up on hind legs “boxing” with other 
rat  
  
General 
contact/near contact 
First move resulting in near contact or contact not involving 
above two actions 
  
 NOTE: record duration of all instances of above 
behaviours 
  
Chase:  
 
any pursuit of stimulus/intruder rat around cage by the 
focal/resident rat -stops as soon as the focal rat stops moving, 
or contact is made (does not include first contact-see above) – 
focal rat must chase over a distance equivalent to length of a 
rat - must include  stimulus/intruder rat moving away from  
focal rat (so not just a move by focal rat towards other rat 
(this would be LTA-aggressive posture above) 
  
Sniffing  any aggressive sniffing of anus/genital region (this may/may 
not include use of paws) - record duration of instances – 
instance stops when sniffing stops for 1 second  
 
  
Alert position:  
 
focal rat exhibits a sudden interruption of all movement with 
head directed towards stimulus/intruder rat-must be perfectly 
still for at least 1 second duration (must be facing other rat - 
not upwards or to side) 
  
Self-groom:  
 
the resident/focal rat grooms itself by licking body fur and/or 
face washing (most often after a fight attack). Instance will 
cease when ever the grooming stops for more than 1 second. 
  
Avoidance Any move greater than the length of a rat that the  
focal/resident rat makes to escape or distance itself from the 
intruder/stimulus rat. Instance stops when movement stops for 
more than 1 second 
 
  
Standing on Hind 
Legs 
Any instance when focal/resident rat stands up on hind legs 
and faces stimulus/intruder rat - does not include when rat is 
doing this to look out top of cage – DOES NOT include 
contact with other rat 
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Appendix C 
 
Aggressive Posture   
 Methamphetamine  
 Mean SEM 
Saline 5.83 1.61 
1mg/kg .33 .33 
2mg/kg .50 .34 
 1-Benzylpiperazine  
10mg/kg .50 .23 
20mg/kg .92 .38 
General/ Non-Aggressive   
 Methamphetamine  
 Mean SEM 
Saline 104.94 55.18 
1mg/kg 19.46 5.30 
2mg/kg 23.73 4.48 
 1-Benzylpiperazine  
10mg/kg 36.03 11.14 
20mg/kg 13.65 2.57 
Chase   
 Methamphetamine  
 Mean SEM 
Saline 5.5 1 
1mg/kg 2.17 .46 
2mg/kg 2.42 .40 
 1-Benzylpiperazine  
10mg/kg 1.83 .61 
 80
20mg/kg 1.83 .47 
Sniffing   
 Methamphetamine  
 Mean SEM 
Saline 13.42 1.79 
1mg/kg 4.42 1.32 
2mg/kg 4 .85 
 1-Benzylpiperazine  
10mg/kg 2.25 .54 
20mg/kg 7.33 2.04 
Alert Position   
 Methamphetamine  
 Mean SEM 
Saline 1.25 .30 
1mg/kg 3.5 .73 
2mg/kg 2.67 .77 
 1-Benzylpiperazine  
10mg/kg 4.67 .1.04 
20mg/kg 2.25 .57 
Self-Grooming   
 Methamphetamine  
 Mean SEM 
Saline 3.67 1.12 
1mg/kg .92 .26 
2mg/kg 1.08 .26 
 1-Benzylpiperazine  
10mg/kg 1.08 .31 
20mg/kg 1.08 .53 
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Avoidance   
 Methamphetamine  
 Mean SEM 
Saline 1.83 .39 
1mg/kg 6 .88 
2mg/kg 6.58 1.75 
 1-Benzylpiperazine  
10mg/kg 1.75 .45 
20mg/kg 1.92 .48 
Up on Hind Legs   
 Methamphetamine  
 Mean SEM 
Saline .75 .28 
1mg/kg 4.75 1.18 
2mg/kg 4.75 .96 
 1-Benzylpiperazine  
10mg/kg 3 .85 
20mg/kg 2.25 .55 
 
 
 
 
 
 
 
 
 
 
